Altimmun announced that it has completed enrollment in its Phase 2 clinical trial of HepTcell, an immunotherapeutic for the treatment of chronic hepatitis B. With the achievement of this milestone, data readout is planned for the first quarter of 2024. The multicenter clinical trial, which is being conducted at 26 sites in North America, Europe and Southeast Asia, enrolled approximately 80 subjects with inactive CHB and low levels of hepatitis B surface antigen. "We are pleased to have achieved this milestone in the HepTcell Phase 2 trial and look forward to the data readout in Q1 2024," said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. "In addition, we look forward to initiating our Phase 2b biopsy non-alcoholic steatohepatitis (NASH) trial in mid-2023 and announcing topline data from our 48-week MOMENTUM obesity trial in the fourth quarter of 2023."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALT:
- Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
- Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors
- Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Altimmune downgraded to Neutral from Buy at Goldman Sachs
